2.12 Microalbuminuria and urinary retinol binding protein as markers of subtle renal injury in visceral leishmaniasis: sensitivity, specificity and predictive values of the immunoturbidimetric technique

Chapters in this book

1. Frontmatter i
2. Preface v
3. Table of Contents vii
4. Authors Index xi
5. 1 Plenary Articles
6. 1.1 Proteomics strategies targeting biomarkers for cardiovascular disease 3
7. 1.2 Influence of pre-examination aspects on result’s validity – are ISO 15189 requirements sufficient and clear? 9
8. 1.3 Posttranslational modifications in tumor diagnosis 12
9. 1.4 Chronic inflammatory disease: a result of complex gene-environment interaction 16
10. 2 Symposium Articles
11. 2.1 Component-array technology diagnostics: a step forward in the study of the sensitization profile of allergic patients 23
12. 2.2 Pediatric metabolic syndrome: pathophysiology and molecular mechanisms 26
13. 2.3 Urinary 8-hydroxydeoxyguanosine as a biomarker of microangiopathic complications in type 2 diabetic patients 30
14. 2.4 Biological variation data: the need for appraisal of the evidence base 35
15. 2.5 Recovery ELISA – a newly-developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy 38
16. 2.6 Genotypic prediction of HIV-1 tropism from plasma and peripheral blood mononuclear cells in the clinical routine laboratory 42
17. 2.7 Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas correlates with tumor size 46
18. 2.8 Serological markers of gastric pathology 50
19. 2.9 BNP as a biomarker of cardiac impairment in neonates with congenital heart diseases 54
20. 2.10 Are 25-hydroxyvitamin D assays fit for purpose? 58
21. 2.11 Update on multiple sclerosis 61
22. 2.12 Microalbuminuria and urinary retinol binding protein as markers of subtle renal injury in visceral leishmaniasis: sensitivity, specificity and predictive values of the immunoturbidimetric technique 65
23. 2.13 Occult hepatitis B virus infection: diagnosis and significance 68
24. 2.14 Unmet needs in chronic kidney disease testing 72
25. 2.15 Towards a national chronic kidney disease testing program 75
26. 2.16 Biochemistry and metabolism of vitamin D 78
27. 2.17 Diagnostics of thalassemia 82
28. 2.18 The specific roles of assessors during accreditation 85
29. 2.19 Laboratory diagnosis of hereditary spherocytosis 88
30. 2.20 Quantification of blood folate forms using stable-isotope dilution ultra performance liquid chromatography tandem mass spectrometry 91
31. 2.21 Evaluation of the new Marburg cerebrospinal fluid model with human spondylopathies 95
32. 2.22 E-learning experiences of national societies of clinical chemistry and laboratory medicine 99
33. 2.23 The experience of Médecins Sans Frontières in laboratory medicine in resource-limited settings 102
34. 2.24 Screening, identifying, and quantifying small molecules by hyphenated mass spectrometry in toxicology and drug monitoring – an update 108
35. 2.25 Analytical quality in the Latin America area 111
36. 2.26 Standardization in molecular diagnostics: definitions and uses of nucleic acid reference materials 116
37. 2.27 Profiling of antiphospolipid antibodies – association with cerebrovascular events in APS 120
38. 2.28 Plasma levels of soluble CD30 and CD40L in pediatric patients after liver transplantation 124
39. 2.29 Diagnostic and prognostic value of presepsin (soluble CD14 subtype) in emergency patients with early sepsis using the new assay PATHFAST presepsin 128
40. 2.30 Diagnostic workup of primary aldosteronism 134
41. 2.31 What should the clinical laboratory and the toxicologist-pharmacologist offer the poisoned patient? 138
42. 2.32 Novel aspects of the von Willebrand factor – platelet glycoprotein IB interaction and signaling 142
43. 2.33 Medical emergencies: what is the laboratory’s role? 143